144 related articles for article (PubMed ID: 23933495)
1. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients.
D'Avolio A; De Nicolò A; Cusato J; Ciancio A; Boglione L; Strona S; Cariti G; Troshina G; Caviglia GP; Smedile A; Rizzetto M; Di Perri G
Antiviral Res; 2013 Oct; 100(1):114-9. PubMed ID: 23933495
[TBL] [Abstract][Full Text] [Related]
2. Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment.
DʼAvolio A; Ciancio A; Siccardi M; Smedile A; Baietto L; Simiele M; Marucco DA; Cariti G; Calcagno A; de Requena DG; Sciandra M; Cusato J; Troshina G; Bonora S; Rizzetto M; Di Perri G
Ther Drug Monit; 2012 Apr; 34(2):165-70. PubMed ID: 22406654
[TBL] [Abstract][Full Text] [Related]
3. Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy.
Amjed S; Saleem HGM; Ullah S; Latif S; Shabana ; Jafar J; Waqar AB
BMC Infect Dis; 2024 Mar; 24(1):301. PubMed ID: 38468199
[TBL] [Abstract][Full Text] [Related]
4. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.
Thompson AJ; Santoro R; Piazzolla V; Clark PJ; Naggie S; Tillmann HL; Patel K; Muir AJ; Shianna KV; Mottola L; Petruzzellis D; Romano M; Sogari F; Facciorusso D; Goldstein DB; McHutchison JG; Mangia A
Hepatology; 2011 Feb; 53(2):389-95. PubMed ID: 21274861
[TBL] [Abstract][Full Text] [Related]
5. Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C.
Delvaux N; Costa VD; Costa MM; Villar LM; Coelho HS; Esberard EB; Flores PP; Brandão-Mello CE; Villela-Nogueira CA; Almeida AJ; Lampe E
Mem Inst Oswaldo Cruz; 2015 Aug; 110(5):636-43. PubMed ID: 26154744
[TBL] [Abstract][Full Text] [Related]
6. Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients.
Nishimura T; Osaki R; Shioya M; Imaeda H; Aomatsu T; Takeuchi T; Okumura Y; Fujiyama Y; Andoh A
Mol Med Rep; 2012 Feb; 5(2):517-20. PubMed ID: 22052220
[TBL] [Abstract][Full Text] [Related]
7. Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients.
Scherzer TM; Stättermayer AF; Stauber R; Maieron A; Strasser M; Laferl H; Schwarzer R; Datz C; Rutter K; Beinhardt S; Steindl-Munda P; Hofer H; Ferenci P
J Hepatol; 2013 Nov; 59(5):964-71. PubMed ID: 23850877
[TBL] [Abstract][Full Text] [Related]
8. ITPA gene variant may protect against anemia induced during pegylated interferon alfa and ribavirin combination treatment in Ukrainian patients with chronic hepatitis C.
Kucherenko A; Pampukha V; Bobrova I ; Moroz L; Livshits L
Tsitol Genet; 2015; 49(2):38-41. PubMed ID: 26030972
[TBL] [Abstract][Full Text] [Related]
9. Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.
Domingo P; Guardiola JM; Salazar J; Torres F; Mateo MG; Pacho C; Del Mar Gutierrez M; Lamarca K; Fontanet A; Martin J; Muñoz J; Vidal F; Baiget M
Antimicrob Agents Chemother; 2012 Jun; 56(6):2987-93. PubMed ID: 22430973
[TBL] [Abstract][Full Text] [Related]
10. Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.
Kurosaki M; Tanaka Y; Tanaka K; Suzuki Y; Hoshioka Y; Tamaki N; Kato T; Yasui Y; Hosokawa T; Ueda K; Tsuchiya K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Matsuura K; Sugauchi F; Enomoto N; Nishida N; Tokunaga K; Mizokami M; Izumi N
Antivir Ther; 2011; 16(5):685-94. PubMed ID: 21817190
[TBL] [Abstract][Full Text] [Related]
11. Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection.
Rau M; Stickel F; Russmann S; Manser CN; Becker PP; Weisskopf M; Schmitt J; Dill MT; Dufour JF; Moradpour D; Semela D; Müllhaupt B; Geier A;
J Hepatol; 2013 Apr; 58(4):669-75. PubMed ID: 23195617
[TBL] [Abstract][Full Text] [Related]
12. Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort.
Eskesen AN; Melum E; Moghaddam A; Bjøro K; Verbaan H; Ring-Larsen H; Dalgard O
Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):890-6. PubMed ID: 22584257
[TBL] [Abstract][Full Text] [Related]
13. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.
Thompson AJ; Fellay J; Patel K; Tillmann HL; Naggie S; Ge D; Urban TJ; Shianna KV; Muir AJ; Fried MW; Afdhal NH; Goldstein DB; McHutchison JG
Gastroenterology; 2010 Oct; 139(4):1181-9. PubMed ID: 20547162
[TBL] [Abstract][Full Text] [Related]
14. Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients.
Ahmed WH; Furusyo N; Zaky S; Eldin AS; Aboalam H; Ogawa E; Murata M; Hayashi J
World J Gastroenterol; 2013 Mar; 19(9):1387-95. PubMed ID: 23538996
[TBL] [Abstract][Full Text] [Related]
15. ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.
Matsuura K; Tanaka Y; Watanabe T; Fujiwara K; Orito E; Kurosaki M; Izumi N; Sakamoto N; Enomoto N; Yatsuhashi H; Kusakabe A; Shinkai N; Nojiri S; Joh T; Mizokami M
J Viral Hepat; 2014 Jul; 21(7):466-74. PubMed ID: 24750345
[TBL] [Abstract][Full Text] [Related]
16. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes.
Naggie S; Rallon NI; Benito JM; Morello J; Rodriguez-Novoa S; Clark PJ; Thompson AJ; Shianna KV; Vispo E; McHutchison JG; Goldstein DB; Soriano V
J Infect Dis; 2012 Feb; 205(3):376-83. PubMed ID: 22158703
[TBL] [Abstract][Full Text] [Related]
17. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.
Ogawa E; Furusyo N; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Oct; 59(4):667-74. PubMed ID: 23707372
[TBL] [Abstract][Full Text] [Related]
18. Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment.
Ampuero J; Del Campo JA; Rojas L; Calleja JL; Cabezas J; Lens S; Crespo J; Forns X; Andrade RJ; Fernández I; Buti M; Millán R; Romero-Gómez M
J Clin Virol; 2015 Jul; 68():56-60. PubMed ID: 26071337
[TBL] [Abstract][Full Text] [Related]
19. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.
Ochi H; Maekawa T; Abe H; Hayashida Y; Nakano R; Kubo M; Tsunoda T; Hayes CN; Kumada H; Nakamura Y; Chayama K
Gastroenterology; 2010 Oct; 139(4):1190-7. PubMed ID: 20637204
[TBL] [Abstract][Full Text] [Related]
20. Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.
Kurosaki M; Tanaka Y; Nishida N; Sakamoto N; Enomoto N; Matsuura K; Asahina Y; Nakagawa M; Watanabe M; Sakamoto M; Maekawa S; Tokunaga K; Mizokami M; Izumi N
J Med Virol; 2013 Mar; 85(3):449-58. PubMed ID: 23297176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
